We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug & Device Products
FDAnews Books Library
Events
Form 483s Database
Publications
Webinar Training Pass
eCFR and Guidances
Books
Clinical Products
Advertising
White Papers
Contact Us
About Us
COVID-19
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Rafael Gonzalez
Rafael Gonzalez
Products
PRODUCTS
Olay LLC
Rafael Gonzalez
and
Dayna I. Martinez
Price:
$117.00
View
Bio Lab – St. Joseph Corp.
Rafael Gonzalez
and
Wanda J. Torres
Price:
$117.00
View
Clendo Industrial Laboratory, Inc.
Enrique Galan
and
Rafael Gonzalez
Price:
$117.00
View
Linde Gas Puerto Rico, Inc.
Rafael Gonzalez
Price:
$117.00
View
Lilly del Caribe, Inc.
Jason F. Chancey
and
Rafael Gonzalez
Price:
$117.00
View
Biolab Company
Rafael Gonzalez
Price:
$117.00
View
St. Jude Medical Puerto Rico, LLC
Rafael Gonzalez
and
Marilyn Santiago
Price:
$117.00
View
Dentsply Prosthetics
Rafael Gonzalez
Price:
$117.00
View
Upcoming Events
10
Aug
Gene & Cell Therapy Regulation: Comparability and Other New Developments
08
Sep
Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections
15
Sep
Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis
20
Sep
Building a World-Class Pharmaceutical Advertising and Promotion Review Program
21
Sep
The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval
22
Sep
FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers
Featured Products
FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485
Selecting and Implementing Electronic Document Management Systems in the EU
Featured Stories
Pulse Biosciences’ CellFX Gets 510(k) Clearance for Expanded Energy Settings
Merck to Face MDL Regarding Gardasil HPV Vaccine Side Effects
Hyris T-Cell Test Gains CE-IVD Mark
FDA Expands Approval of Bayer’s Nubeqa for Prostate Cancer
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
